Bissonette Robert, Bergeron Annie, Liu Younan
Division of Dermatology, University of Montreal Hospital Centre, Notre Dame Hospital, 1560 Sherbrooke Street East, Room K-5201, Montreal, Quebec, Canada H2L 4M1.
J Drugs Dermatol. 2004 Jan-Feb;3(1 Suppl):S26-31.
Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) is currently approved in the US and Canada for the spot treatment of non-hypertrophic actinic keratoses of the face and scalp. Dermatologists are currently using ALA-PDT on larger skin surfaces for the treatment of extensive actinic keratoses, sun damage P and acne. This article reviews the safety and efficacy of large surface ALA-PDT for the treatment of actinic keratoses and photodamage. New data on the carcinogenic potential of weekly topical ALA-PDT in mice is also presented. Groups of hairless mice were treated weekly with either ALA alone, blue light alone or ALA-PDT using blue light for a total of 10 months followed by an additional 2 months or observation. Mice were examined weekly for the presence of skin tumors. Skin tumors were not observed in mice treated weekly with blue light alone, with topical application of ALA alone or with ALA-PDT.
外用氨基乙酰丙酸（ALA）的光动力疗法（PDT）目前在美国和加拿大被批准用于面部和头皮非肥厚性光化性角化病的点状治疗。皮肤科医生目前正在将ALA-PDT用于更大面积的皮肤表面，以治疗广泛性光化性角化病、日光损伤P和痤疮。本文综述了大面积ALA-PDT治疗光化性角化病和光损伤的安全性和有效性。还展示了每周外用ALA-PDT对小鼠致癌潜力的新数据。将无毛小鼠分组，每周分别单独用ALA、单独用蓝光或使用蓝光进行ALA-PDT治疗，共持续10个月，随后再观察2个月。每周检查小鼠是否出现皮肤肿瘤。单独每周用蓝光治疗、单独外用ALA或进行ALA-PDT治疗的小鼠均未观察到皮肤肿瘤。
